Plasma TAFI and soluble CD40 ligand do not predict reperfusion following thrombolysis for acute myocardial infarction
Thrombolytic therapy fails to achieve reperfusion in almost a third of patients with acute myocardial infarction. Thrombin activatable fibrinolysis inhibitor (TAFI) and soluble CD40 ligand (sCD40L) are novel endogenous fibrinolytic and atherothrombotic factors that determine clot stability. We inves...
Gespeichert in:
| Veröffentlicht in: | Thrombosis research 2006, Vol.118 (2), p.189-197 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 197 |
|---|---|
| container_issue | 2 |
| container_start_page | 189 |
| container_title | Thrombosis research |
| container_volume | 118 |
| creator | Cruden, Nicholas L.M. Graham, Catriona Harding, Scott A. Ludlam, Christopher A. Fox, Keith A.A. Newby, David E. |
| description | Thrombolytic therapy fails to achieve reperfusion in almost a third of patients with acute myocardial infarction. Thrombin activatable fibrinolysis inhibitor (TAFI) and soluble CD40 ligand (sCD40L) are novel endogenous fibrinolytic and atherothrombotic factors that determine clot stability. We investigated whether admission plasma thrombin activatable fibrinolysis inhibitor (TAFI) and soluble CD40 ligand (sCD40L) concentrations predicted reperfusion following thrombolytic therapy in patients with acute myocardial infarction.
Prior to administration of thrombolytic therapy, venous blood was collected from 110 patients presenting with acute ST segment elevation myocardial infarction and plasma assayed for tissue plasminogen activator (t-PA) antigen and activity, plasminogen activator inhibitor type-1 antigen (PAI-1), TAFI antigen and activity, C-reactive protein (CRP) and sCD40L concentrations. Reperfusion was determined using continuous ST segment monitoring.
Reperfusion occurred in 77 (70%) patients with a mean treatment to reperfusion time of 83
±
46 min. Peak creatine kinase was significantly lower in patients who reperfused (1578
±
1199 versus 2200
±
1744 U/L;
P
<
0.05) and correlated with time to reperfusion (
r
=
0.44 [95% CI: 0.23 – 0.61],
P
=
0.0001). There was a modest correlation between plasma TAFI antigen and activity (
r
=
0.3 [95% CI: 0.04 – 0.53];
P
<
0.05). There were no significant associations between coronary reperfusion and plasma concentrations of t-PA, PAI-1, TAFI, CRP or sCD40L.
Systemic plasma TAFI, sCD40L and CRP concentrations do not predict reperfusion in patients receiving thrombolytic therapy for acute ST elevation myocardial infarction. |
| doi_str_mv | 10.1016/j.thromres.2005.06.014 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68043881</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0049384805002756</els_id><sourcerecordid>68043881</sourcerecordid><originalsourceid>FETCH-LOGICAL-c396t-55661ef200a1eacac9ee5fe5329ce8ff71c2f197ca4e227a8695381b6b2dfdf93</originalsourceid><addsrcrecordid>eNqFkcFu1DAQhi0EotvCK1S-wC3BdmLHuVEttFSqBIdytibOuHjlxIudgPbt8bKLeuQ00uj7PTOfCbnmrOaMqw-7evmR4pQw14IxWTNVM96-IBuuu74SbSdekg1jbV81utUX5DLnHWO84718TS64YlLyrtmQ9VuAPAF9vLm9pzCPNMewDgHp9lPLaPBPx94Y6RwXuk84ervQhHtMbs0-ztTFEOJvPz_Rv_sMMRyyz6WdKNh1QTodooU0egjUzw6SXUrsDXnlIGR8e65X5Pvt58ftl-rh69399uahsk2vlkpKpTi6ciBwBAu2R5QOZSN6i9q5jlvheN9ZaFGIDrTqZaP5oAYxutH1zRV5f3p3n-LPFfNiJp8thgAzxjUbpVnbaM0LqE6gTTHnhM7sk58gHQxn5ijc7Mw_4eYo3DBlivASvD5PWIcJx-fY2XAB3p0ByBaCSzBbn5-5Tpf_EapwH08cFh-_PCaTrcfZFuUJ7WLG6P-3yx8FG6TE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68043881</pqid></control><display><type>article</type><title>Plasma TAFI and soluble CD40 ligand do not predict reperfusion following thrombolysis for acute myocardial infarction</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Cruden, Nicholas L.M. ; Graham, Catriona ; Harding, Scott A. ; Ludlam, Christopher A. ; Fox, Keith A.A. ; Newby, David E.</creator><creatorcontrib>Cruden, Nicholas L.M. ; Graham, Catriona ; Harding, Scott A. ; Ludlam, Christopher A. ; Fox, Keith A.A. ; Newby, David E.</creatorcontrib><description>Thrombolytic therapy fails to achieve reperfusion in almost a third of patients with acute myocardial infarction. Thrombin activatable fibrinolysis inhibitor (TAFI) and soluble CD40 ligand (sCD40L) are novel endogenous fibrinolytic and atherothrombotic factors that determine clot stability. We investigated whether admission plasma thrombin activatable fibrinolysis inhibitor (TAFI) and soluble CD40 ligand (sCD40L) concentrations predicted reperfusion following thrombolytic therapy in patients with acute myocardial infarction.
Prior to administration of thrombolytic therapy, venous blood was collected from 110 patients presenting with acute ST segment elevation myocardial infarction and plasma assayed for tissue plasminogen activator (t-PA) antigen and activity, plasminogen activator inhibitor type-1 antigen (PAI-1), TAFI antigen and activity, C-reactive protein (CRP) and sCD40L concentrations. Reperfusion was determined using continuous ST segment monitoring.
Reperfusion occurred in 77 (70%) patients with a mean treatment to reperfusion time of 83
±
46 min. Peak creatine kinase was significantly lower in patients who reperfused (1578
±
1199 versus 2200
±
1744 U/L;
P
<
0.05) and correlated with time to reperfusion (
r
=
0.44 [95% CI: 0.23 – 0.61],
P
=
0.0001). There was a modest correlation between plasma TAFI antigen and activity (
r
=
0.3 [95% CI: 0.04 – 0.53];
P
<
0.05). There were no significant associations between coronary reperfusion and plasma concentrations of t-PA, PAI-1, TAFI, CRP or sCD40L.
Systemic plasma TAFI, sCD40L and CRP concentrations do not predict reperfusion in patients receiving thrombolytic therapy for acute ST elevation myocardial infarction.</description><identifier>ISSN: 0049-3848</identifier><identifier>EISSN: 1879-2472</identifier><identifier>DOI: 10.1016/j.thromres.2005.06.014</identifier><identifier>PMID: 16055173</identifier><identifier>CODEN: THBRAA</identifier><language>eng</language><publisher>New York, NY: Elsevier Ltd</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Biological and medical sciences ; Blood and lymphatic vessels ; C-Reactive Protein - metabolism ; Carboxypeptidase B2 - blood ; Cardiology. Vascular system ; CD40 Ligand - blood ; Coronary heart disease ; Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous ; Female ; Fibrinolysis ; Heart ; Humans ; Male ; Medical sciences ; Middle Aged ; Myocardial infarction ; Myocardial Infarction - blood ; Myocardial Reperfusion ; Neurology ; Plasminogen Activator Inhibitor 1 - blood ; Reperfusion ; Solubility ; Thrombolytic Therapy ; Time Factors ; Tissue Plasminogen Activator - blood ; Vascular diseases and vascular malformations of the nervous system</subject><ispartof>Thrombosis research, 2006, Vol.118 (2), p.189-197</ispartof><rights>2005 Elsevier Ltd</rights><rights>2006 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c396t-55661ef200a1eacac9ee5fe5329ce8ff71c2f197ca4e227a8695381b6b2dfdf93</citedby><cites>FETCH-LOGICAL-c396t-55661ef200a1eacac9ee5fe5329ce8ff71c2f197ca4e227a8695381b6b2dfdf93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0049384805002756$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,4010,27900,27901,27902,65534</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17884826$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16055173$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cruden, Nicholas L.M.</creatorcontrib><creatorcontrib>Graham, Catriona</creatorcontrib><creatorcontrib>Harding, Scott A.</creatorcontrib><creatorcontrib>Ludlam, Christopher A.</creatorcontrib><creatorcontrib>Fox, Keith A.A.</creatorcontrib><creatorcontrib>Newby, David E.</creatorcontrib><title>Plasma TAFI and soluble CD40 ligand do not predict reperfusion following thrombolysis for acute myocardial infarction</title><title>Thrombosis research</title><addtitle>Thromb Res</addtitle><description>Thrombolytic therapy fails to achieve reperfusion in almost a third of patients with acute myocardial infarction. Thrombin activatable fibrinolysis inhibitor (TAFI) and soluble CD40 ligand (sCD40L) are novel endogenous fibrinolytic and atherothrombotic factors that determine clot stability. We investigated whether admission plasma thrombin activatable fibrinolysis inhibitor (TAFI) and soluble CD40 ligand (sCD40L) concentrations predicted reperfusion following thrombolytic therapy in patients with acute myocardial infarction.
Prior to administration of thrombolytic therapy, venous blood was collected from 110 patients presenting with acute ST segment elevation myocardial infarction and plasma assayed for tissue plasminogen activator (t-PA) antigen and activity, plasminogen activator inhibitor type-1 antigen (PAI-1), TAFI antigen and activity, C-reactive protein (CRP) and sCD40L concentrations. Reperfusion was determined using continuous ST segment monitoring.
Reperfusion occurred in 77 (70%) patients with a mean treatment to reperfusion time of 83
±
46 min. Peak creatine kinase was significantly lower in patients who reperfused (1578
±
1199 versus 2200
±
1744 U/L;
P
<
0.05) and correlated with time to reperfusion (
r
=
0.44 [95% CI: 0.23 – 0.61],
P
=
0.0001). There was a modest correlation between plasma TAFI antigen and activity (
r
=
0.3 [95% CI: 0.04 – 0.53];
P
<
0.05). There were no significant associations between coronary reperfusion and plasma concentrations of t-PA, PAI-1, TAFI, CRP or sCD40L.
Systemic plasma TAFI, sCD40L and CRP concentrations do not predict reperfusion in patients receiving thrombolytic therapy for acute ST elevation myocardial infarction.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biological and medical sciences</subject><subject>Blood and lymphatic vessels</subject><subject>C-Reactive Protein - metabolism</subject><subject>Carboxypeptidase B2 - blood</subject><subject>Cardiology. Vascular system</subject><subject>CD40 Ligand - blood</subject><subject>Coronary heart disease</subject><subject>Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous</subject><subject>Female</subject><subject>Fibrinolysis</subject><subject>Heart</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Myocardial infarction</subject><subject>Myocardial Infarction - blood</subject><subject>Myocardial Reperfusion</subject><subject>Neurology</subject><subject>Plasminogen Activator Inhibitor 1 - blood</subject><subject>Reperfusion</subject><subject>Solubility</subject><subject>Thrombolytic Therapy</subject><subject>Time Factors</subject><subject>Tissue Plasminogen Activator - blood</subject><subject>Vascular diseases and vascular malformations of the nervous system</subject><issn>0049-3848</issn><issn>1879-2472</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkcFu1DAQhi0EotvCK1S-wC3BdmLHuVEttFSqBIdytibOuHjlxIudgPbt8bKLeuQ00uj7PTOfCbnmrOaMqw-7evmR4pQw14IxWTNVM96-IBuuu74SbSdekg1jbV81utUX5DLnHWO84718TS64YlLyrtmQ9VuAPAF9vLm9pzCPNMewDgHp9lPLaPBPx94Y6RwXuk84ervQhHtMbs0-ztTFEOJvPz_Rv_sMMRyyz6WdKNh1QTodooU0egjUzw6SXUrsDXnlIGR8e65X5Pvt58ftl-rh69399uahsk2vlkpKpTi6ciBwBAu2R5QOZSN6i9q5jlvheN9ZaFGIDrTqZaP5oAYxutH1zRV5f3p3n-LPFfNiJp8thgAzxjUbpVnbaM0LqE6gTTHnhM7sk58gHQxn5ijc7Mw_4eYo3DBlivASvD5PWIcJx-fY2XAB3p0ByBaCSzBbn5-5Tpf_EapwH08cFh-_PCaTrcfZFuUJ7WLG6P-3yx8FG6TE</recordid><startdate>2006</startdate><enddate>2006</enddate><creator>Cruden, Nicholas L.M.</creator><creator>Graham, Catriona</creator><creator>Harding, Scott A.</creator><creator>Ludlam, Christopher A.</creator><creator>Fox, Keith A.A.</creator><creator>Newby, David E.</creator><general>Elsevier Ltd</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>2006</creationdate><title>Plasma TAFI and soluble CD40 ligand do not predict reperfusion following thrombolysis for acute myocardial infarction</title><author>Cruden, Nicholas L.M. ; Graham, Catriona ; Harding, Scott A. ; Ludlam, Christopher A. ; Fox, Keith A.A. ; Newby, David E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c396t-55661ef200a1eacac9ee5fe5329ce8ff71c2f197ca4e227a8695381b6b2dfdf93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biological and medical sciences</topic><topic>Blood and lymphatic vessels</topic><topic>C-Reactive Protein - metabolism</topic><topic>Carboxypeptidase B2 - blood</topic><topic>Cardiology. Vascular system</topic><topic>CD40 Ligand - blood</topic><topic>Coronary heart disease</topic><topic>Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous</topic><topic>Female</topic><topic>Fibrinolysis</topic><topic>Heart</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Myocardial infarction</topic><topic>Myocardial Infarction - blood</topic><topic>Myocardial Reperfusion</topic><topic>Neurology</topic><topic>Plasminogen Activator Inhibitor 1 - blood</topic><topic>Reperfusion</topic><topic>Solubility</topic><topic>Thrombolytic Therapy</topic><topic>Time Factors</topic><topic>Tissue Plasminogen Activator - blood</topic><topic>Vascular diseases and vascular malformations of the nervous system</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cruden, Nicholas L.M.</creatorcontrib><creatorcontrib>Graham, Catriona</creatorcontrib><creatorcontrib>Harding, Scott A.</creatorcontrib><creatorcontrib>Ludlam, Christopher A.</creatorcontrib><creatorcontrib>Fox, Keith A.A.</creatorcontrib><creatorcontrib>Newby, David E.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Thrombosis research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cruden, Nicholas L.M.</au><au>Graham, Catriona</au><au>Harding, Scott A.</au><au>Ludlam, Christopher A.</au><au>Fox, Keith A.A.</au><au>Newby, David E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Plasma TAFI and soluble CD40 ligand do not predict reperfusion following thrombolysis for acute myocardial infarction</atitle><jtitle>Thrombosis research</jtitle><addtitle>Thromb Res</addtitle><date>2006</date><risdate>2006</risdate><volume>118</volume><issue>2</issue><spage>189</spage><epage>197</epage><pages>189-197</pages><issn>0049-3848</issn><eissn>1879-2472</eissn><coden>THBRAA</coden><abstract>Thrombolytic therapy fails to achieve reperfusion in almost a third of patients with acute myocardial infarction. Thrombin activatable fibrinolysis inhibitor (TAFI) and soluble CD40 ligand (sCD40L) are novel endogenous fibrinolytic and atherothrombotic factors that determine clot stability. We investigated whether admission plasma thrombin activatable fibrinolysis inhibitor (TAFI) and soluble CD40 ligand (sCD40L) concentrations predicted reperfusion following thrombolytic therapy in patients with acute myocardial infarction.
Prior to administration of thrombolytic therapy, venous blood was collected from 110 patients presenting with acute ST segment elevation myocardial infarction and plasma assayed for tissue plasminogen activator (t-PA) antigen and activity, plasminogen activator inhibitor type-1 antigen (PAI-1), TAFI antigen and activity, C-reactive protein (CRP) and sCD40L concentrations. Reperfusion was determined using continuous ST segment monitoring.
Reperfusion occurred in 77 (70%) patients with a mean treatment to reperfusion time of 83
±
46 min. Peak creatine kinase was significantly lower in patients who reperfused (1578
±
1199 versus 2200
±
1744 U/L;
P
<
0.05) and correlated with time to reperfusion (
r
=
0.44 [95% CI: 0.23 – 0.61],
P
=
0.0001). There was a modest correlation between plasma TAFI antigen and activity (
r
=
0.3 [95% CI: 0.04 – 0.53];
P
<
0.05). There were no significant associations between coronary reperfusion and plasma concentrations of t-PA, PAI-1, TAFI, CRP or sCD40L.
Systemic plasma TAFI, sCD40L and CRP concentrations do not predict reperfusion in patients receiving thrombolytic therapy for acute ST elevation myocardial infarction.</abstract><cop>New York, NY</cop><pub>Elsevier Ltd</pub><pmid>16055173</pmid><doi>10.1016/j.thromres.2005.06.014</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0049-3848 |
| ispartof | Thrombosis research, 2006, Vol.118 (2), p.189-197 |
| issn | 0049-3848 1879-2472 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68043881 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Adult Aged Aged, 80 and over Biological and medical sciences Blood and lymphatic vessels C-Reactive Protein - metabolism Carboxypeptidase B2 - blood Cardiology. Vascular system CD40 Ligand - blood Coronary heart disease Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous Female Fibrinolysis Heart Humans Male Medical sciences Middle Aged Myocardial infarction Myocardial Infarction - blood Myocardial Reperfusion Neurology Plasminogen Activator Inhibitor 1 - blood Reperfusion Solubility Thrombolytic Therapy Time Factors Tissue Plasminogen Activator - blood Vascular diseases and vascular malformations of the nervous system |
| title | Plasma TAFI and soluble CD40 ligand do not predict reperfusion following thrombolysis for acute myocardial infarction |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T13%3A44%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Plasma%20TAFI%20and%20soluble%20CD40%20ligand%20do%20not%20predict%20reperfusion%20following%20thrombolysis%20for%20acute%20myocardial%20infarction&rft.jtitle=Thrombosis%20research&rft.au=Cruden,%20Nicholas%20L.M.&rft.date=2006&rft.volume=118&rft.issue=2&rft.spage=189&rft.epage=197&rft.pages=189-197&rft.issn=0049-3848&rft.eissn=1879-2472&rft.coden=THBRAA&rft_id=info:doi/10.1016/j.thromres.2005.06.014&rft_dat=%3Cproquest_cross%3E68043881%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68043881&rft_id=info:pmid/16055173&rft_els_id=S0049384805002756&rfr_iscdi=true |